Cargando…

Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the European Association of Urology Guidelines Using Long-term Data from the European Randomised Study of Screening for Prostate Cancer Rotterdam

BACKGROUND: Guidelines on androgen deprivation therapy (ADT) for prostate cancer (PCa) arise from a critical appraisal of scientific evidence, which is a costly effort. Despite these efforts and the side effects of ADT, guidelines may not always be adhered to. OBJECTIVE: To determine ADT overtreatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Hogenhout, Renée, de Vos, Ivo I., Remmers, Sebastiaan, Venderbos, Lionne D.F., Busstra, Martijn B., Roobol, Monique J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334877/
https://www.ncbi.nlm.nih.gov/pubmed/35911085
http://dx.doi.org/10.1016/j.euros.2022.06.004
_version_ 1784759203592667136
author Hogenhout, Renée
de Vos, Ivo I.
Remmers, Sebastiaan
Venderbos, Lionne D.F.
Busstra, Martijn B.
Roobol, Monique J.
author_facet Hogenhout, Renée
de Vos, Ivo I.
Remmers, Sebastiaan
Venderbos, Lionne D.F.
Busstra, Martijn B.
Roobol, Monique J.
author_sort Hogenhout, Renée
collection PubMed
description BACKGROUND: Guidelines on androgen deprivation therapy (ADT) for prostate cancer (PCa) arise from a critical appraisal of scientific evidence, which is a costly effort. Despite these efforts and the side effects of ADT, guidelines may not always be adhered to. OBJECTIVE: To determine ADT overtreatment in PCa patients compared to the European Association of Urology (EAU) guidelines, and to identify predictors and physicians’ motivations for this overtreatment. DESIGN, SETTING, AND PARTICIPANTS: Men were included from the European Randomised study of Screening for Prostate Cancer (ERSPC) Rotterdam who were diagnosed with PCa between 2001 and 2019, and received ADT <1 yr after diagnosis. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patients were categorised into the concordant ADT or discordant ADT group following the EAU guidelines. Physicians’ motivations for discordancy were reported. Multivariable logistic regression was performed to identify predictors for guideline-discordant ADT including the nonlinear fit of the year of diagnosis. RESULTS AND LIMITATIONS: Of 3608 PCa patients, 1037 received ADT <1 yr after diagnosis. Adherence improved gradually over the study period, resulting in overall discordancy of 15%. A patient diagnosed in 2011 had 3.3 times lower risk on guideline-discordant ADT than a patient diagnosed in 2004 (odds ratio [OR] 0.30; 95% confidence interval [CI] 0.18–0.50). The most common reason for discordancy was unwillingness or unfitness for curative treatment of asymptomatic patients. Age (OR 1.19; 95% CI 1.15–1.24) and Gleason score ≥4 + 3 (OR 1.70; 95% CI 1.06–2.74) were associated with guideline-discordant ADT. CONCLUSIONS: In a Dutch cohort, slow adaptation of the EAU guidelines on ADT for PCa patients between 2001 and 2019 resulted in overall overtreatment of 15%, mostly in asymptomatic patients who were unfit or unwilling for curative treatment. Clear, structured presentation, or integration of these tailored guidelines into the electronic health record might accelerate the adaptation of future guidelines. PATIENT SUMMARY: Slow adaptation of the guidelines on hormonal therapy resulted in overtreatment in 15% of prostate cancer patients, mostly in asymptomatic patients who were unfit or unwilling for curative treatment.
format Online
Article
Text
id pubmed-9334877
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-93348772022-07-30 Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the European Association of Urology Guidelines Using Long-term Data from the European Randomised Study of Screening for Prostate Cancer Rotterdam Hogenhout, Renée de Vos, Ivo I. Remmers, Sebastiaan Venderbos, Lionne D.F. Busstra, Martijn B. Roobol, Monique J. Eur Urol Open Sci Prostate Cancer BACKGROUND: Guidelines on androgen deprivation therapy (ADT) for prostate cancer (PCa) arise from a critical appraisal of scientific evidence, which is a costly effort. Despite these efforts and the side effects of ADT, guidelines may not always be adhered to. OBJECTIVE: To determine ADT overtreatment in PCa patients compared to the European Association of Urology (EAU) guidelines, and to identify predictors and physicians’ motivations for this overtreatment. DESIGN, SETTING, AND PARTICIPANTS: Men were included from the European Randomised study of Screening for Prostate Cancer (ERSPC) Rotterdam who were diagnosed with PCa between 2001 and 2019, and received ADT <1 yr after diagnosis. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patients were categorised into the concordant ADT or discordant ADT group following the EAU guidelines. Physicians’ motivations for discordancy were reported. Multivariable logistic regression was performed to identify predictors for guideline-discordant ADT including the nonlinear fit of the year of diagnosis. RESULTS AND LIMITATIONS: Of 3608 PCa patients, 1037 received ADT <1 yr after diagnosis. Adherence improved gradually over the study period, resulting in overall discordancy of 15%. A patient diagnosed in 2011 had 3.3 times lower risk on guideline-discordant ADT than a patient diagnosed in 2004 (odds ratio [OR] 0.30; 95% confidence interval [CI] 0.18–0.50). The most common reason for discordancy was unwillingness or unfitness for curative treatment of asymptomatic patients. Age (OR 1.19; 95% CI 1.15–1.24) and Gleason score ≥4 + 3 (OR 1.70; 95% CI 1.06–2.74) were associated with guideline-discordant ADT. CONCLUSIONS: In a Dutch cohort, slow adaptation of the EAU guidelines on ADT for PCa patients between 2001 and 2019 resulted in overall overtreatment of 15%, mostly in asymptomatic patients who were unfit or unwilling for curative treatment. Clear, structured presentation, or integration of these tailored guidelines into the electronic health record might accelerate the adaptation of future guidelines. PATIENT SUMMARY: Slow adaptation of the guidelines on hormonal therapy resulted in overtreatment in 15% of prostate cancer patients, mostly in asymptomatic patients who were unfit or unwilling for curative treatment. Elsevier 2022-07-02 /pmc/articles/PMC9334877/ /pubmed/35911085 http://dx.doi.org/10.1016/j.euros.2022.06.004 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Prostate Cancer
Hogenhout, Renée
de Vos, Ivo I.
Remmers, Sebastiaan
Venderbos, Lionne D.F.
Busstra, Martijn B.
Roobol, Monique J.
Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the European Association of Urology Guidelines Using Long-term Data from the European Randomised Study of Screening for Prostate Cancer Rotterdam
title Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the European Association of Urology Guidelines Using Long-term Data from the European Randomised Study of Screening for Prostate Cancer Rotterdam
title_full Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the European Association of Urology Guidelines Using Long-term Data from the European Randomised Study of Screening for Prostate Cancer Rotterdam
title_fullStr Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the European Association of Urology Guidelines Using Long-term Data from the European Randomised Study of Screening for Prostate Cancer Rotterdam
title_full_unstemmed Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the European Association of Urology Guidelines Using Long-term Data from the European Randomised Study of Screening for Prostate Cancer Rotterdam
title_short Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the European Association of Urology Guidelines Using Long-term Data from the European Randomised Study of Screening for Prostate Cancer Rotterdam
title_sort detailed evaluation of androgen deprivation overtreatment in prostate cancer patients compared to the european association of urology guidelines using long-term data from the european randomised study of screening for prostate cancer rotterdam
topic Prostate Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334877/
https://www.ncbi.nlm.nih.gov/pubmed/35911085
http://dx.doi.org/10.1016/j.euros.2022.06.004
work_keys_str_mv AT hogenhoutrenee detailedevaluationofandrogendeprivationovertreatmentinprostatecancerpatientscomparedtotheeuropeanassociationofurologyguidelinesusinglongtermdatafromtheeuropeanrandomisedstudyofscreeningforprostatecancerrotterdam
AT devosivoi detailedevaluationofandrogendeprivationovertreatmentinprostatecancerpatientscomparedtotheeuropeanassociationofurologyguidelinesusinglongtermdatafromtheeuropeanrandomisedstudyofscreeningforprostatecancerrotterdam
AT remmerssebastiaan detailedevaluationofandrogendeprivationovertreatmentinprostatecancerpatientscomparedtotheeuropeanassociationofurologyguidelinesusinglongtermdatafromtheeuropeanrandomisedstudyofscreeningforprostatecancerrotterdam
AT venderboslionnedf detailedevaluationofandrogendeprivationovertreatmentinprostatecancerpatientscomparedtotheeuropeanassociationofurologyguidelinesusinglongtermdatafromtheeuropeanrandomisedstudyofscreeningforprostatecancerrotterdam
AT busstramartijnb detailedevaluationofandrogendeprivationovertreatmentinprostatecancerpatientscomparedtotheeuropeanassociationofurologyguidelinesusinglongtermdatafromtheeuropeanrandomisedstudyofscreeningforprostatecancerrotterdam
AT roobolmoniquej detailedevaluationofandrogendeprivationovertreatmentinprostatecancerpatientscomparedtotheeuropeanassociationofurologyguidelinesusinglongtermdatafromtheeuropeanrandomisedstudyofscreeningforprostatecancerrotterdam
AT detailedevaluationofandrogendeprivationovertreatmentinprostatecancerpatientscomparedtotheeuropeanassociationofurologyguidelinesusinglongtermdatafromtheeuropeanrandomisedstudyofscreeningforprostatecancerrotterdam